SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

ALN-5288

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating1/10
Trial phase
unknown (no public trial record found)
Time to market
unknown, no clinical trial or development stage could be verified
Why 1/10
No scheduled catalyst of any kind can be identified for ALN-5288: the code appears in no web coverage retrievable this session and in no local trial/FDA/catalyst/press record, so there is no dated binary to anchor a share-price move, per the rubric an unverifiable, apparently early/unannounced program with nothing scheduled scores at the bottom of the 0-2 band.
Actionable Insight NEUTRAL

Treat any claim about this specific drug as unverified, the stock's near-term drivers are other programs (e.g., the April 2026 cemdisiran NDA submitted by Regeneron), not ALN-5288.

Price Chart

Loading chart...

Executive Summary

ALN-5288 is an Alnylam Pharmaceuticals development code with no verifiable public profile. SecBot's internal data corroborates the ticker (ALNY = Alnylam Pharmaceuticals, Inc., confirmed via SEC filings) but contains zero references to ALN-5288 across trials, FDA actions/catalysts, press releases, and events. Alnylam is a large, well-covered RNAi company (stock ~$205.52 as of 2026-07-31; analyst consensus buy with a mean target of ~$427.61), but that valuation rests on its marketed and later-stage programs, not on this unverified code. Rating is neutral because there is nothing grounded to be bullish or bearish about for this specific drug.

How It Works

Unknown and unverified. Alnylam's core platform is RNAi therapeutics (drugs that silence disease-causing genes), but no source retrieved this session describes what ALN-5288 targets or how it works, it may be an early, undisclosed candidate, or the code may not correspond to a real public program.

Trial Status

No verifiable trial status. Searches of SecBot's ingested ClinicalTrials.gov records, FDA catalyst data, and press/events tables returned zero matches for "ALN-5288" or "5288" linked to Alnylam. The only "5288" match anywhere was an unrelated GSK hepatitis B vaccine trial (NCT03866187).

The Two-Sided Case

▲ Bull Case3
Parent company is a legitimately large-cap, well-covered RNAi developer: 29 of 38 rated analysts are Buy/Strong Buy with a mean price target of ~$427.61 vs. ~$204.20 current, and Alnylam files regularly with the SEC (10-Q filed 2026-07-30).
If ALN-5288 is a genuine early-stage Alnylam candidate, it would sit inside a pipeline with proven RNAi delivery and multiple marketed drugs, but this is inference about the platform, not evidence about this drug.
Recent tracked-manager 13F data shows institutional accumulation in ALNY (multiple new/add/doubled positions in 2026-Q1/Q2 filings), indicating broad sponsorship of the company, not of this molecule.
▼ Bear Case2
With no mechanism, indication, or trial stage verified, any investment thesis built on this code is speculation; there is no dated catalyst to trade, so the stock cannot be expected to move on ALN-5288 in the next 12 months.
Company-level context is not all bullish: the 90-day evidence checklist also logged insider Form 4 sales (director David Pyott, June 2026, 10b5-1-plan flagged), several tracked-manager exits/severe trims, and a weighted short-volume ratio of ~0.48 over 60 sessions, noise for this drug, but it underscores that ALNY's price action is driven by its other programs.

Upcoming Catalysts

  • None identifiable for ALN-5288 specifically.
  • Company-level context (not this drug): Regeneron submitted an NDA for Alnylam-partnered cemdisiran in generalized myasthenia gravis on 2026-04-30, a real, dated regulatory event for the company.
  • Alnylam earnings/Q2 report: 8-K earnings release filed 2026-07-30, watch management commentary for any mention of new early-stage ALN codes.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov